Title:
Amphotericin B therapy in children with visceral leishmaniasis: Daily vs. alternate day, a randomized trial

dc.contributor.authorUtpal Kant Singh
dc.contributor.authorRajniti Prasad
dc.contributor.authorBir Prakash Jaiswal
dc.contributor.authorPrabhat Kumar Singh
dc.contributor.authorC.P. Thakur
dc.date.accessioned2026-02-07T05:00:01Z
dc.date.issued2010
dc.description.abstractA randomized study was carried out to compare the efficacy and adverse reactions of daily vs. alternate day regimens of amphotericin B in children with visceral leishmaniasis (VL). Six hundred and five children of VL below 14 years of age were randomized into two groups; Group A (302), who received amphotericin B at a dose of 1 mg kg. -1 day. -1 for 15 days and Group B (303); same doses but on alternate days. All patients in both groups were cured, who had completed course of amphotericin B therapy. None had relapsed at 1 and 6 months of follow-up. Adverse reactions in both groups were non-significant. The duration of stay and cost of therapy was significantly lower in Group A children who left the hospital against medical advice, which was also significantly more in Group B. Thus, daily regimen of amphotericin B is equally effective, well tolerated, not more toxic and cost-effective than alternate day regimen, which is currently practiced. © The Author [2010]. Published by Oxford University Press. All rights reserved.
dc.identifier.doi10.1093/tropej/fmp132
dc.identifier.issn1426338
dc.identifier.urihttps://doi.org/10.1093/tropej/fmp132
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/22016
dc.publisherOxford University Press
dc.subjectAmphotericin B
dc.subjectTherapy
dc.subjectVisceral leishmaniasis
dc.titleAmphotericin B therapy in children with visceral leishmaniasis: Daily vs. alternate day, a randomized trial
dc.typePublication
dspace.entity.typeArticle

Files

Collections